Modeling cognitive endophenotypes of schizophrenia in mice

Christoph Kellendonk¹,²,³, Eleanor H. Simpson¹,³ and Eric R. Kandel¹,³,⁴,⁵

¹Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
²Department of Pharmacology, Columbia University, 630 West 168th Street, New York, NY 10032, USA
³The Lieber Center for Schizophrenia Research, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
⁴Department of Neuroscience, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
⁵Howard Hughes Medical Institute, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA

Schizophrenia is a complex mental disorder that is still characterized by its symptoms rather than by biological markers because we have only a limited knowledge of its underlying molecular basis. In the past two decades, however, technical advances in genetics and brain imaging have provided new insights into the biology of the disease. Based on these advances we are now in a position to develop animal models that can be used to test specific hypotheses of the disease and explore mechanisms of pathogenesis. Here, we consider some of the insights that have emerged from studying in mice the relationship between defined genetic and molecular alterations and the cognitive endophenotypes of schizophrenia.

Introduction

The past year has brought a transformation in studying the genetics of schizophrenia. Like for most mental disorders, schizophrenia has a strong genetic component, as evidenced by family and twin studies. A monozygotic twin of a patient with schizophrenia has a 50% likelihood to also develop the disorder, whereas the prevalence in the general population is only 0.7%. However, despite a plethora of genetic association studies, even the most interesting and promising candidate genes for schizophrenia risk have failed to be replicated in multiple populations [1]. Most of the candidate genes that have been studied involve common allelic variants that individually confer only a slight increase in risk (odd ratios <2). Individually they cannot be responsible for the disease. Based on these findings, a ‘common disease–common allele’ model has been proposed according to which many different common allelic variants act in combination to confer predisposition for the disease. In addition, it is thought that some gene variants, or combinations of variants, might only become pathogenic under certain environmental conditions, adding another level of complexity. It is, therefore, not surprising that individual, often statistically underpowered, studies lead to conflicting results. To circumvent the problem of statistical power, a meta-analysis has recently been performed that analyzed >1000 published genetic association studies confirming that some common genetic risk factors are indeed consistently associated with schizophrenia [2]. This meta-analysis is regularly updated with newly published information and is freely accessible at www.szgene.org.

The common disease–common allele model is based on the idea that most disease-related mutations in the human genome are single nucleotide polymorphisms (SNPs). However, recent systematic studies of the human genome have revealed a completely new mechanism of mutations consisting not of SNPs but of variations (duplications and deletions) of large segments of DNA ranging in size from thousands to millions of nucleotides and often involving many genes. These copy number variations (CNVs) have now been mapped systematically and contribute to nucleotide diversity to a larger extent than SNPs.

As a result, this past year several papers have been published that directly challenge the common disease–common allele model and suggest that schizophrenia results from a common disease–rare allele model, according to which a large diversity of rare genetic variants individually account for a high risk for schizophrenia [3–6]. The new studies find that patients with schizophrenia carry more CNVs than healthy controls and that some CNVs are highly enriched in patients and could be causative. In the extreme, this model implies that one family, or even one individual patient, could be the only existing carrier of one causative mutation, given that some cases might result from de novo mutations [6]. The common and rare allele models are not necessarily exclusive and it is likely that rare and common alleles interact in the generation of schizophrenia.

Irrespective of the mechanism, genetic association studies involving either SNPs or CNVs do not establish causative relationships. Neither do they reveal anything about the mechanism by which the affected molecule might be involved in the disease. To study the biological function of the genetic variants implicated in association studies, and to test their influence on biological processes affected in schizophrenia, animal models are crucial. Mice have emerged here, as in the study of other brain diseases, as the best mammalian genetic system in which to test targeted molecular alterations. Despite all obvious limitations, studying genetically modified mice is proving extremely valuable in the understanding of the cognitive deficits of schizophrenia. In this article we discuss the advantages and disadvantages of using genetically modified mice in the study of schizophrenia. We give examples
of mouse models that have given important insights into the function of rare structural mutations and common allelic variants. In addition, because mouse models are helpful in studying the behavioral consequences of specific molecular alterations, they can be used to study specific hypotheses of the disease and mechanisms of pathogenesis. In this context we describe one recent model that is based on the dopamine hypothesis of schizophrenia in which a molecular alteration observed in patients has been modeled in the mouse.

Historically, schizophrenia is characterized by positive, negative and cognitive symptoms

Historically, schizophrenia has been characterized by three sets of symptoms: the positive, negative and cognitive. The positive or psychotic symptoms refer to false perceptions (hallucinations), abnormal believes (delusions) and disordered thought processes. The negative symptoms refer to social withdrawal, lack of motivation and abnormalities in social interaction. The cognitive symptoms refer to deficits in attention and working memory that lead to an inability to organize one’s life and to work effectively. The reason why schizophrenia is characterized by its symptoms is because we do not know enough about the biological basis of the disease to develop biological markers that can be used for its diagnosis. However, recent technological advances in genetics and brain imaging have identified biological abnormalities that can help us to understand the etiology of the disease. Table 1 summarizes some of the most reliable biological alterations in schizophrenia.

**Modeling cognitive endophenotypes of schizophrenia in mice**

Obviously it is impossible to model schizophrenia in its entirety including the positive, negative and cognitive

<table>
<thead>
<tr>
<th>General observations</th>
<th>Specific observations</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic contributing factors</td>
<td>Top candidate genes for common alleles with low risk</td>
<td>[4–6,105]</td>
</tr>
<tr>
<td>Concordance in monozygotic twins is ~50%, in dizygotic twins it is 15%</td>
<td>Vesicular monoamine transporter 1 (SLC18A1) NR2B subunit of NMDA receptor (GRIN2B) β2 subunit of the GABA&lt;sub&gt;A&lt;/sub&gt; receptor (GABRB2) Dopamine D&lt;sub&gt;2&lt;/sub&gt; receptor (DRD2) Semaphoring receptor (PLXNA2)</td>
<td></td>
</tr>
<tr>
<td>Rare structural mutations with high risk</td>
<td>1q21.1, 15q13.3 and 22q11 deletions t(1;11) translocation</td>
<td></td>
</tr>
<tr>
<td>Environmental contributing factors</td>
<td>Risk factors during pregnancy</td>
<td>[104,106,107,122,123]</td>
</tr>
<tr>
<td>Concordance in monozygotic twins is not 100%</td>
<td>Maternal infections Malnutrition</td>
<td></td>
</tr>
<tr>
<td>Risk factors during adolescence</td>
<td>Marijuana use during early adolescence Stress</td>
<td></td>
</tr>
<tr>
<td>Developmental abnormalities</td>
<td>MRI studies:</td>
<td>[108,109,124]</td>
</tr>
<tr>
<td>Early symptoms including motor disturbances and speech difficulties during infancy</td>
<td>Exaggerated cortical gray matter loss during adolescence in early-onset patients with schizophrenia</td>
<td></td>
</tr>
<tr>
<td>Molecular alterations</td>
<td>Alterations in the dopaminergic system</td>
<td>[92,94,95,110–113]</td>
</tr>
<tr>
<td>All neurotransmitter systems might be affected in schizophrenia</td>
<td>Most antipsychotic drugs block dopamine D&lt;sub&gt;2&lt;/sub&gt; receptors Postmortem and PET imaging studies: Increased amphetamine induced dopamine release (striatum) Increased dopamine precursor uptake (striatum) Increased density and occupancy of D&lt;sub&gt;2&lt;/sub&gt; receptors (striatum) Altered density of D&lt;sub&gt;1&lt;/sub&gt; receptors (cortex) Decreased tyrosine hydroxylase immunoreactivity (cortex)</td>
<td></td>
</tr>
<tr>
<td>Alterations in the GABAergic system</td>
<td>Postmortem studies: Decreased GAD67 and GAT1 immunoreactivity (cortex) Increased GABA&lt;sub&gt;A&lt;/sub&gt; immunoreactivity (cortex) Alterations in the glutamatergic system Chronic blockage of NMDA receptors leads to positive, negative and cognitive symptoms of schizophrenia mGluR2/3 agonists are the first non-D&lt;sub&gt;2&lt;/sub&gt; blockers that alleviate positive symptoms</td>
<td></td>
</tr>
<tr>
<td>Anatomical changes</td>
<td>Structural MRI studies:</td>
<td>[114–118]</td>
</tr>
<tr>
<td>Several brain areas show structural alterations</td>
<td>Enlarged ventricles Decreased volumes of hippocampus, striatum and thalamus Structural alteration in prefrontal cortex Postmortem studies: Decreases in prefrontal neuropil Decreases in thalamic neurons</td>
<td></td>
</tr>
<tr>
<td>Functional changes</td>
<td>Functional brain imaging:</td>
<td>[119]</td>
</tr>
<tr>
<td>Altered activation of the prefrontal cortex during behavioral tasks that address the cognitive symptoms of schizophrenia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
symptoms in the mouse. The positive symptoms are particularly difficult to model because we cannot measure hallucinations or delusions in mice. However, mice can be used to study specific endophenotypes of the disease. Endophenotypes are individually measured traits or markers of a disease that alone represent only a component of the disease and, therefore, are often subclinical [7]. The use of endophenotypes was pioneered by Brown and Goldstein [8] who measured low-density lipoprotein (LDL) receptor levels as a subclinical endophenotype of atherosclerosis. They determined that the lack of adequate LDL receptors is the cause of familial hypercholesterolemia and heavily predisposes to atherosclerosis. An example of an endophenotype in schizophrenia is working memory as tested and scored in the N-back test. The idea underlying the endophenotype approach is that the genotype that is responsible for one specific endophenotype might be less complex than the genotype underlying the whole disease. In consequence, there might be a direct link between an individual gene and a specific endophenotype. There are both strengths and weaknesses to using the endophenotype approach in psychiatric genetics, which are discussed by Walters and Owen [9].

Some endophenotypes, especially those related to the cognitive symptoms, are tractable in the mouse. Kraepelin already recognized that patients with dementia praecox (i.e. schizophrenia) share many of the behavioral abnormalities observed in patients with lesions of the frontal cortex [10]. Both patients with prefrontal lesions and with dementia praecox are impaired in working memory, attention and other prefrontal dependent cognitive processes [11–14]. Based on imaging and lesion studies, working memory and behavioral flexibility have been associated specifically with the dorso-lateral prefrontal cortex (PFC) in humans and non-human primates [12,15]. Anatomical and lesion studies suggest that the homolog of the dorso-lateral PFC in primates is the medial PFC in the rat [15–17]. Because of the utility of mouse genetic models, lesion studies have more recently been completed that extend this functional homology from rats to mice. To date, the mouse medial PFC has been found to be required for working memory tasks, conditioned associative learning,

<table>
<thead>
<tr>
<th>Cognitive domains</th>
<th>Test administered to humans</th>
<th>Test administered to mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attentional set shifting</td>
<td>Wisconsin card sorting task</td>
<td>Attentional set shifting task</td>
</tr>
<tr>
<td>Cognitive flexibility</td>
<td>Subjects must sort cards by a single feature (e.g. color) and then, without instruction, ‘shift set’ to sort them by a different category (e.g. shape or number).</td>
<td>Subjects learn to associate a reward with a specific cue, for example an odor. Without instruction the rewarded cue might change to a different odor (intradimensional shift) or a different dimension, for example texture (extradimensional shift).</td>
</tr>
<tr>
<td>Spatial working memory</td>
<td>Spatial working memory task</td>
<td>Maze based delayed non-match to sample tasks</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>Various shaped mazes (e.g. Y, T, 8-arm radial) might be used. Subjects must enter a maze arm, which was previously not baited, to retrieve subsequent food rewards.</td>
</tr>
<tr>
<td></td>
<td>Delay (1–90s)</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td>Match to sample</td>
<td>Non match to sample</td>
</tr>
<tr>
<td></td>
<td>Subjects must remember the spatial location of an object and determine if it matches the original sample.</td>
<td></td>
</tr>
<tr>
<td>Conditional associative learning</td>
<td>Visual conditional learning test</td>
<td>Operant based conditional associative learning</td>
</tr>
<tr>
<td></td>
<td>By trial and error subjects must work although the deck of cards to determine the pre-established pattern–color associations arbitrarily chosen by the examiner.</td>
<td>By trial and error subjects must learn to associate two distinct stimuli with two arbitrarily associated outcomes (e.g. high frequency tone, left lever press is rewarded; low frequency tone, right lever press is rewarded).</td>
</tr>
<tr>
<td>Sustained attention</td>
<td>Continuous performance test</td>
<td>5-choice serial reaction time test</td>
</tr>
</tbody>
</table>
attentional set shifting and reversal learning [18–22]. This suggests that cognitive processes that are dependent on the PFC can be studied in the mouse as it has been done in the rat. Table 2 provides examples of mouse tasks that we and others designed to capture the cognitive processes underlying the successful performance of homologous tasks in humans. Although these homologous tasks use different sensory modalities, temporal schedules, rewards and motor demands in the two species, they each require PFC function and it is likely that they are solved by similar mental and physiological strategies.

Because the cognitive symptoms of schizophrenia present early in the disease and their severity is highly predictive of the long-term prognosis, understanding these symptoms is central for understanding schizophrenia. Moreover, unlike the positive symptoms, the cognitive symptoms are largely resistant to current treatment and persist throughout the lifetime of the individual, greatly compromising the patient's ability to function effectively in society. The great advantage of using mouse genetics to study schizophrenia is that it enables the establishment of a causal relationship between genotype and cognitive endophenotypes, a relationship that cannot be addressed in humans. In turn, this knowledge could lead to the development of more effective therapy in humans. Here, we describe three different categories of mouse models that have been used to explore the cognitive endophenotypes of schizophrenia.

**Mouse models based on copy number variants**

*22q11 deletion syndrome*

1:4000 newborns carry heterozygous deletions on chromosome 22 in the q11 region [23]. This deletion has a highly

---

**Figure 1.** Studying the 22q11 deletion in mice. The top shows the 1.5 megabase region of chromosome (chr.) 22 that is deleted in 22q11 carriers in humans. The syntenic region in the mouse is located on chromosome 16. The names of the genes in both regions are colored to emphasize the difference in the organization of the loci. Chromosomal deletions: seven chromosomal 16 deletions of different lengths that have been generated in the mouse and analyzed for behavior are shown [38–40]. Individual gene knockouts: eight knockout mice have been analyzed for behavior [41,77,120,121]. Behavioral analysis: comparative summary of the behavioral analysis of the 15 different mouse models. Because only one copy is deleted in the 22q11 deletion, the behavioral analysis of heterozygous mice are shown unless only homozygous mice (\(^/-\)) have been evaluated. *Denotes that a deficit in pre-pulse inhibition was observed in Tbx1 heterozygous mutant mice when backcrossed to C57b6 but not on a mixed genetic background.
variable clinical presentation. Before the associated chromosomal deletion was identified, the variability of clinical features led to the description of a variety of syndromes including velocardiofacial syndrome, DiGeorge syndrome and others [24]. In ~90% of cases the deletion spans 3 megabases, whereas in 8% of cases the deletion is only 1.5 megabases long. Almost all patients suffer from craniofacial abnormalities and over half suffer from cardiovascular disorders [25,26]. Patients also display cognitive deficits that range from impairments in working memory, executive function and mild learning disabilities to mental retardation [27,28]. About 30% of adult patients with 22q11 deletion syndromes are diagnosed with psychiatric disorders including schizophrenia and bipolar disorder, anxiety and affective disorders [25,26]. Patients also display cognitive deficits that range from impairments in working memory, executive function and mild learning disabilities to mental retardation [27,28]. About 30% of adult patients with 22q11 deletion syndromes are diagnosed with psychiatric disorders.

The relative risk for schizophrenia in a patient with 22q11DS is 20–25 times the lifetime general population risk of ~1%. Because the deletion confers such a high risk for schizophrenia, the genes that are rendered hemizygous by the deletion are promising candidate genes for study.

To understand which genes in the 22q11 deletion might be responsible for the different physical and behavioral phenotypes, mouse models of the deletion have been developed [32,33]. In the mouse the syntenic region is located on chromosome 16 and it carries almost all of the genes of the human 22q11 region although the organization of the locus is altered (Figure 1). In an elegant collection of studies performed by several laboratories, the transcription factor Tbx-1 has been identified as the mediator for some of the physical alterations observed in the 22q11 deletion syndrome [34–37] (Figure 1). First, the 1.5 megabase deletion was introduced into the mouse genome resulting in cardiovascular abnormalities comparable to those observed in patients. Second, several sub-deletions were generated that enabled narrowing down the number of potential candidate genes, and a small genomic fragment carrying these genes could rescue the deletion phenotype when expressed from an artificial chromosome. Third, targeted inactivation of one copy of the Tbx-1 gene revealed that haploinsufficiency of this gene alone led to the cardiovascular phenotype.

The same strategy has been used to identify the genes responsible for the behavioral abnormalities. So far, the behavioral analysis has largely focused on testing prepulse inhibition (PPI), a measure for sensory motor gating that is impaired in patients with certain mental illnesses including schizophrenia and patients with the 22q11 deletion syndrome [38–40] (Figure 1). In these studies mice with heterozygous deletion of individual genes from the deletion region were tested for PPI and they showed PPI deficits if they carried individual mutations in three genes: Dger8, Gnb1l and Tbx-1. This indicates that the sensorimotor gating defect in patients with deletions is not due to haploinsufficiency of any one individual gene. Dger8 by itself might also contribute to the deficit in working memory observed in carriers of the deletion [40]. The Dger8 gene is interesting because it encodes a double-stranded RNA-binding protein that is involved in the processing of immature micro RNAs (miRNAs) to mature miRNAs. In consequence, Dger8 heterozygous mice show reduced mature miRNAs [40]. Because miRNAs are regulators of protein expression, the altered Dger8 expression might have strong pleiotropic effects. More studies are needed to see whether additional genes in the deletion might be responsible for the behavioral deficits of the deletion carriers. Conceivably different genes interact in their hemizygous state in the modulation of cognitive processes. Indeed, a functional interaction between two 22q11 genes, the Prodh gene (which encodes proline dehydrogenase) and the Cont gene (which encodes catechol-O-methyltransferase, COMT), has already been demonstrated [41].

The balanced t(1;11) translocation affecting DISC1

In 1990 St Clair et al. [42] characterized a Scottish family that carried a balanced autosomal translocation and suffered a high prevalence of mental illness. From the 29 carriers of the translocation, seven were later diagnosed with schizophrenia, one with bipolar disorder and ten with depression [43]. Positional cloning identified two genes DISC1 and DISC2 that are disrupted by the translocation [44]. Although this translocation has only been identified in one family, the high incidence of a mental disorder point to DISC1, DISC2 and other genes close to the translocation break point as interesting candidate genes for psychosis and affective disorders. In addition, two large independent association studies have identified haplotypes within the DISC1 gene that seem to contribute to genetic risk for schizophrenia [45,46]. So far, molecular studies have been focused on DISC1 because DISC2 does not code for a protein. However, DISC2 might code for a regulatory RNA that could have biological importance.

DISC1 seems to serve as a scaffolding protein interacting with many proteins ranging from transcription factors, phosphodiesterases, cytoskeletal proteins to centrosomal proteins [47–53]. As a result, the function of DISC1 might be important for a variety of cell biological processes. Consistent with this idea, studies in cell culture and in vivo studies in Drosophila melanogaster and mouse found that disruption of DISC1 affects intracellular signaling, gene expression and cytoskeletal function, in addition to neuronal migration, positioning, differentiation and neurite extension [49,53–55]. Expression of DISC1 is widespread in the brain and is strong during embryonic development. In the adult brain, expression is largely restricted to the granule cells of the hippocampus and to the neurons in the olfactory bulb, two neuronal populations that are regenerated in the adult mouse [56]. The expression studies and the functional studies, therefore, suggest that altered DISC1 function owing to the translocation might affect brain development.

To study the consequences of altered Disc1 function on endophenotypes involved in depression and schizophrenia, seven different mouse models have been generated (Figure 2). Four of these overexpress a transdominant-negative peptide in the brain. Three of the four overexpress the truncated protein or N-terminal peptide that could potentially be made in human t(1;11) carriers but the presence of which has not yet been validated [49,57–60]. Because the translocation disrupts the coding sequence, the transcribed mRNA might not be polyadenylated and might, therefore, be unstable and not translated. The
fourth mouse model expresses a peptide from the C-terminal part of DISC1 that binds two interacting partners of DISC1, NUDEL and LIS1. One possible limitation of this transgenic approach is that transgenic DISC1 is overexpressed constantly throughout development and into adulthood. However, there are very dynamic changes in DISC1 expression during development. In mice there is one sharp peak of expression around embryonic day 13.5 and a second dramatic increase in expression level at puberty [61]. One model circumvents this problem by using the endogenous Disc1 promoter to express the peptide [60]. Moreover, because DISC1 interacts with many proteins, overexpression might unspecifically interfere with the function of these proteins.

Figure 2. Studying the function of Disc1 in the mouse. Top left shows the structure of the Disc1 gene on mouse chromosome 8. Below the genomic loci or the transgenic constructs of seven genetically modified mice are depicted. Mutations in the mouse Disc1 locus: three mouse models carry mutations in the mouse Disc1 locus. Two models carry missense mutations in exon 2 introduced by chemical-induced mutagenesis screen (Disc1Rgsc1390 and Disc1Rgsc1393) [62]. The third model, Disc1Tm1Kara [63,64], features a stop codon in exon 8 and a polyadenylation signal (pA) after this exon to model the breakpoint of the human translocation. However, because this mutation was generated in a 129S6/SvEv background it also carries an intrinsic stop codon in exon 7 resulting in an N-terminal peptide that ends at amino acid 542. This peptide is 50 amino acid smaller than the 597 amino acid long N-terminal peptide that could potentially be expressed in t(1;11) carriers. Transgenic mouse models: four transgenic mouse models have been generated that all overexpress truncated DISC1 proteins or peptides in neurons of the brain of the mouse. One expresses the truncated DISC1 protein suggested to be present in t(1;11) carriers from the endogenous Disc1 mouse locus using a bacterial artificial chromosome that spans 148 kb of the Disc1 gene [60]. This strategy prevents ectopic expression of the transgene. In this mouse DISC1 is fused to enhanced green fluorescent protein (GFP) to visualize protein expression. Three models use the CamKIIa promoter to restrict expression to the forebrain. Two models overexpress the N-terminal 597 amino acid peptide: Tg(CamK2a-Disc1)10Asaw [57] and Tg(CamK2a-tTA)1Mmay×Tg(TRE-CMV-hDisc1) [58]. Note that for the second mouse model the expression of transgenic DISC1 can be regulated at the level of transcription using the tetracycline transactivator (tTA) system. The tTA transcription factor drives expression from the tetO promoter in the absence of doxycycline. When animals are fed with a doxycycline-supplemented diet, tTA dissociates from the promoter and the transgene is switched off. The third mouse model expresses a C-terminal peptide designed to work as a transdominant negative protein by sequestering out the binding partners NUDEL or LIS1 [59]. The peptide is fused to a mutated ligand-binding domain of the estrogen receptor, permitting regulation of the activity of the fusion protein. Treating the animals with the synthetic steroid tamoxifen activates the fusion protein. Behavioral analysis: the right side gives a comparative summary of the behavioral analysis performed with the six mouse models. * Denotes that the deficit in spatial reference memory of Tg(CamK2a-tTA)1Mmay×Tg(TRE-CMV-hDisc1) mice was observed in females but not in males.
In addition to the four transgenic mouse lines, three models have been generated that are germ-line mutations. Two models carry missense mutations, of which the immediate functional impact is not known, and one model carries a Disc1 gene that encodes the truncated peptide [62–64]. Although these missense mutations importantly link mutations in the Disc1 gene to phenotypes related to schizophrenia, they might not be directly comparable to the human genetic variations involved in the disease because the amino acid sequences involved are not conserved between humans and rodents [65]. The germ-line mutation that expresses the truncated peptide is probably closest to the situation in human t(1;11) carriers, although it might still express DISC1 isoforms that are not present in translocation carriers [66].

Together, these models show quite clearly that altering DISC1 function leads to deficits in endophenotypes of schizophrenia and depression including deficits in sensory-motor gating, spatial working memory, social interaction and the forced swim test (Figure 2). In line with the role of DISC1 in regulating neuronal morphology, all mouse models show morphological alterations in the brain that are similar to the ones observed in patients with schizophrenia (Table 1). For example, some models were assayed by structural magnetic imaging (MRI) and showed increased lateral ventricles or decreased brain size reminiscent of MRI studies performed in patients with schizophrenia [57,58,62]. Of particular interest is the finding in one model, in which the activity of the transdominant DISC1 peptide could be artificially regulated (Figure 2), that affecting DISC1 function during early postnatal development was sufficient to induce behavioral abnormalities in the adult animal [59]. This is in line with the neurodevelopmental hypothesis of schizophrenia and consistent with the apparent role DISC1 is thought to have.

**Mouse models based on associations with common polymorphisms**

The Val158Met polymorphism in the Comt gene

A common human polymorphism in the 22q11 COMT gene, the Val158Met polymorphism, affects the stability and thereby the activity of the enzyme. This polymorphism has been implicated in many diseases and disease traits including schizophrenia [67,68]. As is the case for many common human polymorphisms, the original association has not always been replicated [69]. However, the Val allele, which confers higher enzymatic activity, seems to be robustly associated with poor performance on working memory and attentional-set shifting tasks, compared with the less active Met allele [68,70,71]. There are also several studies identifying differences in brain activation between genotypes [72]. It is usually assumed that increased COMT activity results in reduced levels of extracellular dopamine in the cortex. In line with this idea, the [11C]NNC D1-specific positron emission tomography (PET) ligand has revealed an increase in D1 receptor density in the PFC of Val allele carriers, which might reflect a compensation for decrease extracellular dopamine levels [73]. Patients with schizophrenia also show an upregulation in cortical D1 receptor availability that correlates with deficits in working memory [74] (but see also Ref. [75]). Because animal studies in rodents and monkeys have found that working memory is sensitive to changes in prefrontal D1 receptor activation, alterations in prefrontal dopamine signaling might be responsible for cognitive deficits of schizophrenia [76]. Understanding the biological relevance of modulated COMT activity might, therefore, provide key inroads into the cognitive symptoms.

To model the increase in enzymatic activity observed in human Val allele carriers, transgenic mice have been generated in which COMT was overexpressed in the brain. As predicted from human studies, increased COMT activity affected executive function including working memory and attentional-set shifting negatively [77]. Amphetamine rescued some of the cognitive deficit, implying that an increase in dopamine release can compensate for COMT overactivity. These mice can now be used to understand the underlying biology of the observed behavioral deficits. For example, they can address the question of whether increased enzymatic COMT activity really reduces extracellular dopamine levels in the cortex, as assumed, and, if so, does it lead to a compensatory upregulation of D1 receptors. Modulation of COMT activity has been postulated as a drug therapy for the cognitive deficits of schizophrenia. To this end, transgenic COMT mice might be useful for testing the efficacy of COMT inhibitors, once suitable brain penetrant versions are available.

**Neuregulin–ErbB signaling**

Several linkage studies in independent populations have identified chromosome 8p as a locus involved in schizophrenia (see meta-analysis in Refs [78,79]). Subsequent fine mapping, haplotype-association analysis and disequilibrium testing identified neuregulin 1 (NRG1) as a strong candidate gene [80,81]. More than 80 SNPs within the gene have now been associated with schizophrenia, either alone or within a haplotype involving multiple SNPs, some of which have been associated with specific endophenotypes such as hypofrontality and decreased premorbid IQ [82]. There are also reports of genetic association for one of NRG1s functional receptors, v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ERBB4) [83]. Expression of both ligand and receptor has been reported to be altered in postmortem cortical tissue from patients with schizophrenia [81]. As with all proposed susceptibility targets for schizophrenia, there are also negative association and expression studies for both genes, but the convergence of the positive findings builds a strong enough case to investigate the function of NRG1–ERBB4 signaling in mice. Several mouse mutations have been published including knockdowns of NRG1 and ERBB receptors, in addition to targeted mutations of specific domains such as the transmembrane, cystein-rich, epidermal growth factor and immunoglobulin-like domains. The behavioral phenotypes of several Nrg1 and ErbB4 mutants have recently been compared [84]. Heterozygous Nrg1 knockout mice, in addition to mice with deletions within the Nrg1 gene, are hyperactive, as are ErbB4 mutant mice; by contrast, ErbB2 and ErbB3 heterozygous mice seem to be behaviorally normal [85,86]. So far, prefrontal-dependent cognition has not been extensively studied in these mouse models, with the exceptions of working memory, which
was found to be intact in heterozygous transmembrane NRG1 mutant mice [87] but impaired in heterozygous type III NRG1 mutant mice [88]. More cognitive studies using several prefrontal-dependent tasks are needed to study the function of NRG1 in cognition.

**Mouse models based on specific hypotheses: the dopamine hypothesis, increased density of striatal D2 receptors**

Based on seminal experiments by Arvid Carlsson and others, Jacques Van Rossum proposed forty years ago that overstimulation of dopamine receptors could be part of the etiology of schizophrenia (for a historical review, see Ref. [89]). The strongest support for the hypothesis comes from the work of Solomon Snyder and Philip Seeman, who found that the efficacies of antipsychotic medications correlate directly with their occupancy of dopamine receptors [90,91]. More recently, brain imaging studies have found both an increase in the release of dopamine and an increase in the density and occupancy of the D2 receptor in the striatum of patients with schizophrenia [92–95]. Several studies suggest that in at least a subpopulation of patients

Figure 3. Overexpression (OE) of dopamine D2 receptors (D2R) selectively in the striatum leads to cognitive and negative-like symptoms. (a) Selective overexpression of dopamine D2 receptors in the striatum using the tTA system (see legend for Figure 2). Although the tTA transcription factor is expressed in the whole forebrain, the tetO-D2R construct response is restricted to the striatum with very limited expression outside of the striatum (gene on) [21]. The transgene can be switched off by feeding the mice doxycycline (Dox; gene off). (b) Cognitive symptoms: excess D2 receptors in the striatum leads to impairments in two prefrontal-dependent cognitive endophenotypes that are also impaired in patients with schizophrenia: working memory and conditioned associative learning [18,21]. Neither deficit is reversed by switching off the transgene in the adult animal. Negative symptoms: an excess of D2 receptors in the striatum also induces impairment in incentive motivation. When required to lever press for food rewards in a progressive ratio schedule, striatal D2R-overexpressing mice stop performing much sooner than control littermates [101]. In contrast to the cognitive deficits, this deficit is reversed by switching off the transgene in the adult animal.
the observed increase in D₂ receptor binding might be determined genetically [96–99].

To study the causal relationship between increased D₂ receptor density in the striatum and schizophrenia endophenotypes, D₂ receptors have been selectively overexpressed in the striatum of the mouse [21] (Figure 3). These mice were created using the bi-transgenic tetracycline-sensitive expression system [100], which provides temporal control of transgene expression. Mice with D₂ receptor overexpression selectively in the striatum show impairments in prefrontal-dependant cognitive processes, which are also affected in schizophrenia. Furthermore, these animals display a decrease in dopamine turnover and an increase in D₁ receptor activation in the PFC that could be responsible for the cognitive deficits [18,21]. In addition to the defect in prefrontal functioning, these mice show a deficit in incentive motivation [101] that relates to the negative symptoms. Most interestingly, the cognitive, but not the motivational, deficits persisted long after expression of the transgene has been switched off. In fact, expression during prenatal development is sufficient to cause cognitive deficits in adulthood.

These findings suggest three important new ideas. First, hyperfunctioning of the mesostriatal dopamine pathway could be primarily involved in the etiology of the cognitive symptoms by affecting the functioning of the PFC. Second, the reason that treatment by means of pharmacological blockade of D₂ receptors has minimal, if any, beneficial effects on the cognitive symptoms of schizophrenia is because antipsychotic medication is given too late, long after irreversible compensatory changes have taken place during development. Third, the cognitive and negative symptoms might share some etiological components, which is consistent with the observation that the severity of these two types of symptoms strongly correlates in patients.

Concluding remarks

In this review we illustrated how mouse models are being used to study the biology that might underlie some of the cognitive endophenotypes of schizophrenia. We have focused on genetic mouse models that attempt to recapitulate three specific types of molecular alterations observed in schizophrenia: (i) rare structural mutations, (ii) common polymorphisms and (iii) striatal dopaminergic hyperfunction. Our discussion was not intended to be complete and we apologize for omitting other models that are interesting in this context.

What have we learned from these mouse models? Most importantly we have learned that there might be a causal link between genetic or molecular alterations observed in schizophrenia and cognitive endophenotypes of schizophrenia. Whereas genetic studies in humans are mainly correlative, the presented genetic mouse models demonstrate that they can be used to study the consequences of specific genetic or molecular alterations. The fact that several Disc1 mouse models show enlarged ventricles and deficits in working memory suggests that Disc1 could also be causally involved in the generation of these endophenotypes in patients that carry the t(1;11) translocation. Moreover, the presented models give insight into possible mechanisms by which molecular alterations affect cognition. One model showed that upregulation of D₂ receptors in the striatum leads to deficits in prefrontal-dependent behavior, possibly by affecting dopamine signaling in the PFC. This interplay between the striatal and prefrontal dopamine systems might not only exist in the mouse, but could also be involved in the generation of the cognitive deficits in patients with schizophrenia.

Although genetic mouse models of schizophrenia and psychiatric disorders in general have been generated for over a decade now, the current generation of studies is proving to be more informative. This is due to several factors: the identification of new genetic risk alleles in humans, the technical advances in mouse genetics (better spatial and temporal resolution) and the development of the field of cognitive endophenotyping in mice. The last point is very important because it provides confidence in the concept of modeling cognitive endophenotypes of schizophrenia in mice.

What can we learn from mouse models in the future? We believe that two areas of research will in particular benefit from the use of mouse models.

(i) The study of gene–gene interactions: according to the common disease–common allele model of schizophrenia, alterations in the function of any individual gene alone do not result in schizophrenia. Even in the common disease–rare allele model, no fully penetrant mutation has yet been identified. By crossing individual genetically modified mice with each other it will be possible to determine how different genes functionally interact.

(ii) The study of gene–environment interactions: even in combination, genetic variations are not sufficient to cause schizophrenia, as evidenced by 50% discordance in homozygotic twins. This fact, along with decades of epidemiological studies, highlights the importance of environmental contributions to the development of the disease. Gene–environment interactions have been studied in patients with psychosis [102]; however, they are difficult to perform in humans because the genetic background and the environmental conditions cannot be rigorously controlled [103]. This, however, can be done in mice, and indeed increased risk for schizophrenia caused by prenatal infection has been modeled in mice. Cytokine induction during pregnancy produces offspring with behavioral and morphological abnormalities in adulthood that are similar to schizophrenia endophenotypes [104]. In the future, the consequences of prenatal infections or other environmental insults can be studied in genetically modified mice. These studies will be of great importance in understanding how genes and the environment interact. Moreover, they might identify risk factors that populations with a specific genetic predisposition might want to avoid.

Acknowledgements

This work was supported by NARSAD (www.narsad.org), the National Institute of Mental Health Silvio O. Conte Center for Schizophrenia Research (www.nimh.nih.gov) and the Lieber Center for Schizophrenia Research. We also are grateful to Harold and Shari Levy whose generous contributions have supported our schizophrenia research.
61 Schurov, I.L. et al. (2004) Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol. Psychiatry 9, 1100–1110
65 Ma, L. et al. (2002) Cloning and characterization of Disc1, the mouse ortholog of DISC1 (Disrupted-in-Schizophrenia 1). Genomics 80, 662–672
66 Ishizuka, K. et al. (2007) Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice. Mol. Psychiatry 12, 897–899
74 Abi-Dargham, A. et al. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708–3719
75 Okubo, Y. et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634–636
76 Goldman-Rakic, P.S. et al. (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 174, 3–16
87 O’Tuathaigh, C.M. et al. (2007) Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1. Neuroscience 147, 18–27
91 Creese, I. et al. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483
93 Abi-Dargham, A. et al. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97, 8104–8109
108 O’Connell, F. et al. (1997) Developmental insanity or dementia praecox: was the wrong concept adopted? Schizophr. Res. 23, 97–106